Roche Confirms Outlook Despite Missing Vabysmo Sales Target
Swiss drugmaker Roche confirmed its 2026 outlook despite missing analyst expectations for sales of its eye drug Vabysmo in the first half. The company's group sales fell slightly to 30.36 billion Swiss francs ($37.34 billion) year-on-year, but operating profit rose 10% at constant exchange rates to 11.86 billion Swiss francs.
Chief Executive Thomas Schinecker said Roche expects most future deal opportunities to come from the U.S. and China. The company's top-selling drugs - multiple sclerosis drug Ocrevus and haemophilia shot Hemlibra - grew 7% and 11% respectively from the same period last year.
Roche is preparing for its next major commercial launch - giredestrant for breast cancer in the U.S. by the end of the year, and will also report data for one of its experimental obesity drugs.